Sanya Thakur
Independent Researcher
India
Abstract
Inclisiran, a small interfering RNA targeting PCSK9, has emerged as a transformative biannual lipid-lowering therapy with the potential to address adherence challenges common in daily and weekly statin-based regimens. This study investigates real-world patient adherence patterns associated with biannual Inclisiran administration across multiple tertiary care centers. By retrospectively analyzing medical records, pharmacy refill data, and follow-up documentation from diverse populations, the study seeks to determine whether the simplified dosing regimen correlates with higher patient adherence, sustained LDL-C reduction, and improved cardiovascular outcomes. Results from this study offer critical insights into the patient behavior surrounding novel lipid-lowering therapies and provide evidence to inform future guideline recommendations and payer coverage decisions. The findings underscore that longer dosing intervals may play a pivotal role in improving long-term compliance among at-risk cardiovascular populations.
Keywords
Inclisiran; PCSK9 Inhibition; Patient Adherence; Biannual Injections; Hyperlipidemia; Cardiovascular Risk; Real-World Study; Lipid Management; Medication Compliance; LDL-C Reduction
References
- Benner, J. S., Glynn, R. J., Mogun, H., Neumann, P. J., Weinstein, M. C., Sacks, F. M., & Avorn, J. (2002). Long-term persistence in use of statin therapy in elderly patients. JAMA, 288(4), 455–461. https://doi.org/10.1001/jama.288.4.455
- Ho, P. M., Magid, D. J., Shetterly, S. M., Olson, K. L., Maddox, T. M., Peterson, P. N., Masoudi, F. A., & Rumsfeld, J. S. (2006). Medication nonadherence is associated with increased hospitalization and mortality: A population-based study. Circulation, 113(23), 2841–2847. https://doi.org/10.1161/CIRCULATIONAHA.105.591255
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., … & Koren, M. J. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine, 372(16), 1500–1509. https://doi.org/10.1056/NEJMoa1500858
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., … & Stein, E. A. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine, 372(16), 1489–1499. https://doi.org/10.1056/NEJMoa1501031
- Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., … & Simon, A. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. The New England Journal of Medicine, 376(1), 41–51. https://doi.org/10.1056/NEJMoa1609222
- Ray, K. K., Robinson, J. G., Farnier, M., Krempf, M., MacDougall, D. E., & Sullivan, D. (2017). Safety and efficacy of alirocumab over 104 weeks in adults with hypercholesterolaemia. International Journal of Cardiology, 238, 1–7. https://doi.org/10.1016/j.ijcard.2017.02.070
- Fischer, M. A., Choudhry, N. K., Brill, G., Avorn, J., Schneeweiss, S., Hutchins, D., & Shrank, W. H. (2010). Trouble getting started: Predictors of primary medication nonadherence. The American Journal of Medicine, 123(9), 707–714. https://doi.org/10.1016/j.amjmed.2010.04.012
- Peterson, G. M., & Naunton, M. (2005). Adherence to long-term therapies: Evidence for action. Medical Journal of Australia, 183(3), 205–206. https://doi.org/10.5694/j.1326-5377.2005.tb06817.x
- Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., … & Haynes, R. B. (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, (11), CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
- Jackevicius, C. A., Li, P., & Tu, J. V. (2002). Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation, 109(13), 1611–1618. https://doi.org/10.1161/01.CIR.0000122007.84860.CC